Roche exercises option for Ionis HD candidate IONIS-HTTRx

Roche (SIX:ROG: OTCQX:RHHBY) exercised an option to in-license Huntington’s disease (HD) candidate IONIS-HTTRx from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), triggering a $45 million payment to Ionis. The companies partnered in 2013 to develop antisense therapies to treat HD (see BioCentury April 15, 2013)...